GENB stock news

GENB stock news. Deduplicated factual headlines, scored for importance, with entity sentiment and the sectors, countries, and asset classes affected. Updates open into the storyline.

See the full wire

20 wire items

2026-10-30 13:15:22 UTC#545855newconfirmednews

Guggenheim maintains Genmab at Buy, raises price target to $80 from $58

tradingviewimportance 0.30trust 0.60Guggenheim Partners, LLC +0.20Genmab A/S +0.20

2026-10-30 09:01:52 UTC#544234updateconfirmednews

Genmab A/S market value increases by $10 billion this week following positive petosemtamab trial data

bloombergimportance 0.50trust 0.90Genmab A/S +0.80

2026-10-29 19:20:00 UTC#540114newconfirmednews

Genmab A/S consensus analyst price target raised to $61.56 from $60.82, Buy rating maintained

tradingviewimportance 0.30trust 0.70Genmab A/S +0.30

2026-10-29 13:32:00 UTC#537759newconfirmednews

Genmab price target raised to $70 from $50 at H.C. Wainwright & Co., Buy rating maintained

dow_jonesimportance 0.40trust 0.70Genmab A/S +0.60H.C. Wainwright & Co. +0.60

2026-10-28 23:11:00 UTC#533291duplicateconfirmednews

Genmab shares rise 28% following positive Phase 3 trial results for petosemtamab in head and neck cancer, WSJ reports

dow_jonesimportance 0.30trust 0.90Genmab A/S +0.80Merck & Co., Inc. +0.30Pembrolizumab +0.30+2 entities

2026-10-28 19:20:00 UTC#531718newconfirmednews

Genmab A/S average analyst price target raised to $49.42 from $48.75, consensus Buy rating maintained

tradingviewimportance 0.30trust 0.70Genmab A/S +0.30

2026-10-28 18:10:15 UTC#531203updateconfirmednews

Genmab reports positive Phase III results for three oncology programs, targeting 2027 product launches

quartrimportance 0.50trust 0.60Genmab A/S +0.60Petosemtamab +0.60

2026-10-28 14:10:00 UTC#529593updateconfirmednews

Genmab reports petosemtamab plus Keytruda reduces death risk by 50% in Phase 3 head and neck cancer trial

seeking alphaimportance 0.60trust 0.70Genmab A/S +0.70Merck & Co., Inc. +0.60Pembrolizumab +0.60

2026-10-28 13:45:27 UTC#529376duplicateconfirmednews

Genmab reports positive Phase 3 LiGeR-HN1 trial results for petosemtamab in head and neck cancer

reutersimportance 0.60trust 0.90Genmab A/S +0.80Petosemtamab +0.80LiGeR-HN1 +0.80

2026-10-28 13:41:00 UTC#529289newconfirmednews

Genmab Phase 3 LiGeR-HN1 trial of petosemtamab plus pembrolizumab meets dual primary endpoints in 1L HNSCC

tradingviewimportance 0.70trust 0.70Genmab A/S +0.80petosemtamab +0.80pembrolizumab +0.20+1 entities

2026-10-27 12:43:00 UTC#521331newconfirmednews

WSJ Health Care Market Talk: Insights on Novartis and Genmab

wsjimportance 0.30trust 0.90Novartis AG 0Genmab A/S 0

2026-10-26 17:37:39 UTC#516363duplicateconfirmednews

European STOXX 600 closes 0.77% higher as Computacenter and Genmab gains lead market recovery

reutersimportance 0.30trust 0.90STOXX 600 +0.40Computacenter plc +0.80Genmab A/S +0.80

2026-10-26 17:11:00 UTC#516263duplicateconfirmednews

TD Cowen maintains Buy rating on Genmab, raises price target to $52.00 from $43.00

dow_jonesimportance 0.30trust 0.70Genmab A/S +0.30TD Cowen +0.30

2026-10-26 17:01:09 UTC#516221newconfirmednews

TD Cowen maintains Buy rating on Genmab, sets $52 price target

tradingviewimportance 0.40trust 0.60Genmab A/S +0.30TD Cowen +0.30Incyte Corporation +0.20+2 entities

2026-10-26 12:54:00 UTC#514741updateconfirmedanalysis

J.P. Morgan upgrades Genmab to overweight, raises price target to 3,500 DKK citing clinical trial success

dow_jonesimportance 0.60trust 0.80Genmab A/S +0.80JPMorgan Chase & Co. +0.60Rina-S +0.50+2 entities

2026-10-26 10:05:00 UTC#513764newconfirmednews

Genmab shares rise 13% as rinatabart sesutecan meets primary goals in late-stage ovarian cancer trial

dow_jonesimportance 0.70trust 0.90Genmab A/S +0.80rinatabart sesutecan +0.80Epkinly +0.30+2 entities

2026-10-26 09:25:16 UTC#513553updateconfirmednews

STOXX 600 up 0.4%; Genmab gains 13% on trial data, Computacenter rises 8% on profit hike, GTT drops 12% on revenue miss

reutersimportance 0.40trust 0.90STOXX +0.20Genmab A/S +0.80Computacenter plc +0.70+1 entities

2026-10-25 11:02:21 UTC#511118newconfirmednews

Genmab reports positive updated Phase 2 results for petosemtamab in metastatic colorectal cancer

reutersimportance 0.40trust 0.80Genmab A/S +0.50petosemtamab +0.50

2026-10-25 11:00:00 UTC#511121duplicateconfirmednews

Genmab reports updated Phase 2 petosemtamab mCRC data with 75% ORR in 1L and 67% in 2L

tradingviewimportance 0.40trust 0.70Genmab A/S +0.60petosemtamab +0.60

2026-10-24 11:00:00 UTC#510115duplicateconfirmednews

Incyte and Genmab announce Phase 1/2 clinical trial collaboration for KRAS G12D-mutated mCRC

tradingviewimportance 0.30trust 0.80Incyte Corporation +0.30Genmab A/S +0.30INCB161734 +0.30+2 entities